Princeton Global Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Princeton Global Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,000	Closed	-$22K	–	548
2022 Q1	$22K	Hold	5,000	–	–	0.01%	348
2021 Q4	$20K	Hold	5,000	–	–	0.01%	335
2021 Q3	$44K	Hold	5,000	–	–	0.01%	266
2021 Q2	$57K	Buy	5,000 +3,500	+233%	+$42.1K	0.02%	247
2021 Q1	$18K	Hold	1,500	–	–	0.01%	335
2020 Q4	$10K	Buy	+1,500	New	+$10.5K	﹤0.01%	384

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Princeton Global Asset Management's ALDX Position: Q2 2022 in Review

Princeton Global Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2022, closing a stake of 5,000 shares — an estimated $22K sold.

Princeton Global Asset Management first reported a position in ALDX in Q4 2020 and held it in 6 quarters. The position peaked at $57K in Q2 2021. 95 funds tracked by Wall St. Rank hold ALDX as of Q2 2022.

Princeton Global Asset Management reported no remaining Aldeyra Therapeutics position as of Q2 2022 after selling out during the quarter.
Princeton Global Asset Management sold 5,000 Aldeyra Therapeutics shares in Q2 2022, an estimated $22K.
Princeton Global Asset Management first reported a position in Aldeyra Therapeutics in Q4 2020 and held it in 6 quarters.
Princeton Global Asset Management's Aldeyra Therapeutics position peaked at $57K in Q2 2021.
95 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2022.

Based on Princeton Global Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.